TPG:NASDAQTPG Inc. Analysis
Data as of 2026-06-17 - not real-time
$44.64
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
TPG’s share price is trading just below a clear resistance zone, with the 20‑day and 50‑day moving averages already beneath the current level, suggesting limited upside in the near term. Technical momentum appears mixed: the MACD histogram is positive and the MACD line sits above its signal, yet the overall trend is flagged as bearish and the RSI hovers in a neutral‑to‑slightly‑bullish range. Volatility is elevated, reflected by a 30‑day swing above thirty percent and a beta well above one, indicating the stock moves more sharply than the market. Fundamentally, the stock looks significantly overvalued with a trailing PE far above industry norms and a DCF fair‑value estimate well below the market price. Despite a robust dividend yield, the company carries a heavy debt load and recent revenue has contracted sharply, raising concerns about long‑term earnings stability. However, forward earnings estimates have improved, and analyst price targets imply a notable upside potential if the earnings turnaround materializes.
The dividend appears sustainable at present, given a very low payout ratio and ample operating cash flow, though free cash flow is currently nil and debt levels are high. The recent announcement of a preferred‑stock dividend adds a short‑term cash return for certain shareholders. Forward‑looking metrics, such as a more reasonable forward PE and positive earnings guidance, support a medium‑term upside thesis, while the high valuation and market sentiment (extreme greed) caution against aggressive short‑term positioning. Overall, the stock sits at a crossroads between short‑term technical resistance and a longer‑term earnings recovery narrative.
The dividend appears sustainable at present, given a very low payout ratio and ample operating cash flow, though free cash flow is currently nil and debt levels are high. The recent announcement of a preferred‑stock dividend adds a short‑term cash return for certain shareholders. Forward‑looking metrics, such as a more reasonable forward PE and positive earnings guidance, support a medium‑term upside thesis, while the high valuation and market sentiment (extreme greed) caution against aggressive short‑term positioning. Overall, the stock sits at a crossroads between short‑term technical resistance and a longer‑term earnings recovery narrative.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near resistance with limited upside
- Mixed technical signals (bullish MACD vs bearish trend)
- High volatility and beta
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Improving forward earnings estimates
- Attractive dividend yield with low payout ratio
- Analyst price targets indicating upside
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Sustained high valuation relative to fundamentals
- Heavy debt burden and recent revenue decline
- Potential for earnings recovery balanced by sector risk
Key Metrics & Analysis
Financial Health
Revenue Growth-56.80%
Profit Margin4.23%
P/E Ratio186.0
ROE10.76%
ROA3.16%
Debt/Equity82.45
P/B Ratio6.0
Op. Cash Flow$1.0B
Industry P/E17.1
Technical Analysis
TrendBearish
RSI59.5
Support$39.25
Resistance$45.31
MA 20$42.08
MA 50$42.56
MA 200$52.42
MACDBullish
VolumeStable
Fear & Greed Index92.13
Valuation
Fair Value$18.52
Target Price$56.00
Upside/Downside25.45%
GradeOvervalued
TypeBlend
Dividend Yield5.02%
Risk Assessment
Beta1.47
Volatility35.62%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.